View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 17, 2021

AXIM enters collaboration to determine Covid-19 antibody levels

The partnership will develop a Covid-19 ‘Correlate of Protection’ using AXIM’s rapid neutralising antibody test.

AXIM Biotechnologies has entered into a collaboration with Arizona State University for an initiative that seeks to identify people with low Covid-19 neutralising antibody levels, who are therefore vulnerable to infection.

Under the collaboration, the partners will develop a Covid-19 ‘Correlate of Protection’ using AXIM’s rapid neutralising antibody test.

AXIM and Arizona State University will conduct a study to determine a threshold when neutralising antibody levels against Covid-19 declines among people.

For this new study, Arizona State University associate professor Douglas Lake will recruit people who are at high-risk, and their neutralising antibody levels will be observed every week using AXIM’s rapid neutralising antibody test.

They will also be tested weekly, using polymerase chain reaction (PCR), for the presence of the SARS-CoV-2 virus in their body.

The determination of a threshold is expected to help in avoiding future infections while also enabling healthcare providers to recommend a booster dose of a Covid-19 vaccine.

Lake said: “We expect that people whose neutralising antibody levels are high will not become infected compared to those that have low levels of neutralising antibodies.

“Using this study design, our goal is to develop a ‘Correlate of Protection’ so that people can keep their antibody levels high enough to avoid infection and potential transmission of the virus to vulnerable populations.”

According to AXIM, measuring the responses of anti-viral T cells is technically and logistically difficult compared to measuring antibodies.

The company’s Covid-19 neutralising antibody test measures the functional neutralising antibodies’ levels, which prevent the SARS-CoV-2 virus from entering the host cells.

AXIM Biotechnologies CEO John Huemoeller said: “When our rapid test indicates that someone’s neutralising antibody levels are low, healthcare providers might recommend a booster dose of Covid-19 vaccine, especially for someone who is high-risk, such as a healthcare provider, teacher, immunosuppressed or elderly.”

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU